Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) shares gapped up before the market opened on Wednesday . Definium Therapeutics shares last traded at $42.85, with a volume of 2,741,718 shares changing hands. More Definium Therapeutics NewsHere are the key news stories impacting Definium Therapeutics this week:Get Definium Therapeutics alerts:Positive Sentiment: Definium announced positive topline results from the Phase 3 Voyage study, saying DT120 ODT reduced anxiety symptoms in patients with generalized anxiety disorder. Definium Therapeutics Company Profile(Get Free Report)Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. Featured ArticlesReceive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.